IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
IN8bio (Nasdaq: INAB) has announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentation will focus on INB-100, a pilot study of donor-derived gamma-delta T cell therapy following haploidentical hematopoietic stem-cell transplantation. Dr. Joseph McGuirk from The University of Kansas Cancer Center will present Abstract #4823 in the Cellular Immunotherapies session on December 9, 2024, from 6:00 PM to 8:00 PM PDT. The abstract will be available online through ASH's website, with poster reprints accessible on IN8bio's website after the presentation.
IN8bio (Nasdaq: INAB) ha annunciato una prossima presentazione di un poster al 66° Congresso Annuale dell'American Society of Hematology (ASH) che si svolgerà a San Diego, dal 7 al 10 dicembre 2024. La presentazione si concentrerà su INB-100, uno studio pilota sulla terapia con cellule T gamma-delta derivate da donatore dopo un trapianto di cellule staminali ematopoietiche haploidentiche. Il Dr. Joseph McGuirk del Kansas Cancer Center presenterà l'Abstract #4823 nella sessione sulle Immunoterapie Cellulari il 9 dicembre 2024, dalle 18:00 alle 20:00 PDT. L'abstract sarà disponibile online tramite il sito web di ASH, con le ristampe del poster accessibili sul sito di IN8bio dopo la presentazione.
IN8bio (Nasdaq: INAB) ha anunciado una próxima presentación de un póster en la 66ª Reunión Anual de la American Society of Hematology (ASH) en San Diego, del 7 al 10 de diciembre de 2024. La presentación se centrará en INB-100, un estudio piloto sobre la terapia con células T gamma-delta derivadas de donantes tras un trasplante de células madre hematopoyéticas haploidénticas. El Dr. Joseph McGuirk del Centro de Cáncer de la Universidad de Kansas presentará el Resumen #4823 en la sesión de Inmunoterapias Celulares el 9 de diciembre de 2024, de 18:00 a 20:00 PDT. El resumen estará disponible en línea a través del sitio web de ASH, y las reimpresiones del póster estarán accesibles en el sitio de IN8bio después de la presentación.
IN8bio (Nasdaq: INAB)는 2024년 12월 7일부터 10일까지 샌디에고에서 열리는 제66회 미국혈액학회(ASH) 연례 회의에서 포스터 발표를 예정하고 있다고 발표했습니다. 이번 발표는 HLA 반일치 조혈모세포 이식 후 기증자 유래 감마-델타 T 세포 요법에 대한 INB-100 임상 시험을 중심으로 진행됩니다. 조셉 맥기르크 박사가 캔자스 대학교 암 센터 소속으로 2024년 12월 9일 오후 6시부터 8시(PDT)까지 세포 면역 요법 세션에서 초록 #4823을 발표합니다. 초록은 ASH 웹사이트를 통해 온라인으로 제공되며, 발표 후 IN8bio 웹사이트에서도 포스터 재인쇄본을 얻을 수 있습니다.
IN8bio (Nasdaq: INAB) a annoncé une future présentation de poster lors de la 66e Réunion Annuelle de l'American Society of Hematology (ASH) à San Diego, du 7 au 10 décembre 2024. La présentation portera sur INB-100, une étude pilote sur la thérapie cellulaire T gamma-delta dérivée de donneurs suite à une transplantation de cellules souches hématopoïétiques haploidentiques. Le Dr Joseph McGuirk du Kansas Cancer Center présentera le Résumé #4823 lors de la session sur les Immunothérapies Cellulaires le 9 décembre 2024, de 18h00 à 20h00 PDT. Le résumé sera disponible en ligne sur le site de l'ASH, et des réimpressions du poster seront accessibles sur le site de IN8bio après la présentation.
IN8bio (Nasdaq: INAB) hat eine kommende Posterpräsentation auf der 66. Jahrestagung der American Society of Hematology (ASH) in San Diego vom 7. bis 10. Dezember 2024 angekündigt. Die Präsentation wird sich auf INB-100 konzentrieren, eine Pilotstudie zur Spender-abgeleiteten Gamma-Delta-T-Zelltherapie nach haploidentischem hämatopoetischen Stammzelltransplantat. Dr. Joseph McGuirk vom Kansas Cancer Center wird am 9. Dezember 2024 im Rahmen der Sitzung zu Zellulären Immuntherapien das Abstract #4823 von 18:00 bis 20:00 PDT präsentieren. Das Abstract wird online über die Website der ASH verfügbar sein, und nach der Präsentation werden die Poster-Drucke über die Website von IN8bio zugänglich sein.
- None.
- None.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.
Details for the ASH 2024 presentation are as follows:
| Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide | |
| Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center | |
| Abstract #: 4823 | |
| Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III | |
| Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT | |
The abstract will be available online and can be accessed via the conference websites at ASH Annual Meeting Abstracts. Reprints of the poster will also be accessible on the Events & Presentations page of IN8bio’s website following the presentations.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
Patrick McCall
IN8bio, Inc.
646.933.5603
pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at the 2024 ASH Annual Meeting?
What is the subject of IN8bio's (INAB) presentation at ASH 2024?
Who is presenting IN8bio's (INAB) research at ASH 2024?
Where can investors find IN8bio's (INAB) ASH 2024 presentation materials?
